Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Ian Hardcastle

Newcastle AuthorsTitleYearFull text
Dr Celine Cano
Professor Jane Endicott
Dr Ian Hardcastle
Dr Claire Jennings
Suzanne Kyle
et al.		Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile2024
Dr Elaine Willmore
Suzanne Kyle
Dr Yan Zhao
Huw Thomas
Dr Kenneth Rankin
et al.		Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index2024
Gemma Davison
Dr Mathew Martin
Dr Shannon Turberville
Selma Dormen
Dr Richard Heath
et al.		Mapping ligand interactions of bromodomains BRD4 and ATAD2 with FragLites and PepLites ─ Halogenated probes of druglike and peptide-like molecular interactions2022
Duncan Miller
Tristan Reuillon
Dr Lauren Molyneux
Dr Tim Blackburn
Dr Noel Edwards
et al.		Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor2022
Islam Al-Khawaldeh
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
et al.		An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)2021
Dr Ian Hardcastle
Dr Ruth Bawn
Dr Tim Blackburn
Dr Celine Cano
Dr Sarah Cully
et al.		Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction2021
Christopher Matheson
Christopher Coxon
Dr Benoit Carbain
Dr Ian Hardcastle
Dr Suzannah Harnor
et al.		2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase2020
Daniel Wood
Daniel Lopez Fernandez
Leanne Knight
Islam Al-Khawaldeh
Dr Conghao Gai
et al.		FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation2019
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.		Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Dr Simon Hill
Dr Michael Dunn
Dr Celine Cano
Dr Suzannah Harnor
Dr Ian Hardcastle
et al.		Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification2018
Duncan Miller
Dr Mathew Martin
Santosh Adhikari
Alfie Brennan
Professor Jane Endicott
et al.		Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach2018
Amy Heptinstall
Dr Celine Cano
Dr Ian Hardcastle
Recent advances in CDK inhibitors for cancer therapy2018
Christopher Coxon
Dr Suzannah Harnor
Dr Mathew Martin
Dr Benoit Carbain
Emeritus Professor Bernard Golding
et al.		Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines2017
Professor David Rees
Emeritus Professor Bernard Golding
Dr Ian Hardcastle
Dr Celine Cano
Duncan Miller
et al.		ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY2017
Professor David Rees
Emeritus Professor Bernard Golding
Dr Ian Hardcastle
Dr Celine Cano
Duncan Miller
et al.		Preparation of isoindolinones as inhibitors of the MDM2-​p53 interaction having anticancer activity2017
12345678